Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812027 · ClinicalTrials.gov registry record
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
A clinical trial of Non-Small Cell Lung Cancer and Head and Neck Cancer, sponsored by TScan Therapeutics.
- Active
- Registry status
- 1,150
- Enrollment target
- 20
- Study locations
NCT05812027 is a study of Non-Small Cell Lung Cancer and Head and Neck Cancer that is active but no longer recruiting, run by TScan Therapeutics. The registered enrollment target is 1,150 participants, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05812027, a study of Non-Small Cell Lung Cancer and Head and Neck Cancer, is active but no longer recruiting, sponsored by TScan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 1,150 participants
- Enrollment target
- 20
- Study locations
Study Summary
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tumor and HLA Profiling
Study Locations (20)
Florida
- Memorial Healthcare System - Hollywood
- University of Miami, Sylvester Comprehensive Cancer Center - Miami
- Orlando Health - Orlando
- University of South Florida - Tampa
Ohio
- Oncology Hematology Care - Cincinnati
- The Cleveland Clinic - Cleveland
Pennsylvania
- Allegheny Hospitals Network - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
Arizona
- HonorHealth Research and Innovation Institute - Scottsdale
California
- University of California San Diego - San Diego
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago - Chicago
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2027-01-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05812027
The ClinicalTrials.gov registry entry for NCT05812027 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 656-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% higher). The listed sponsor is TScan Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumor and HLA Profiling is the first listed.
NCT05812027 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05812027 about?
NCT05812027 is a clinical study titled "A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors". TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to ...
What is the current status of trial NCT05812027?
This trial is currently active not recruiting. The enrollment target is 1,150 participants. The study started on 2023-06-26. Estimated completion is 2027-01-14.
What conditions does trial NCT05812027 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer, Cervical Cancer, Sarcoma, Uveal Melanoma.
What interventions are being tested in trial NCT05812027?
The interventions under investigation include: Tumor and HLA Profiling (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05812027?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05812027 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.